Dror Berman
Investor (Seed round and on) @ Color
San Francisco, United States
Dror Berman is a Series A investor at Color in San Francisco focused on Software and Health Care. Dror Berman is the Managing partner at Innovation Endeavors.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Dror Berman invests in
Stages Dror Berman invests in
Countries Dror Berman invests in
Investment Focus
Industry
- Software 3 (15%)
- Health Care 3 (15%)
- Medical 2 (10%)
- Advertising 2 (10%)
- Biotechnology 2 (10%)
Stage
- Series A 6 (30%)
- Seed 3 (15%)
- Series B 3 (15%)
- Angel 1 (5%)
- Series C 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jest
|
Jest offers messaging games that are built for the texting era. Jest allows frictionless, no-download gameplay that is optimized for maximum retention and growth. | $7M / Seed / Feb 26, 2026 | |
Cosmos Innovation
|
Cosmos Innovation specialize in full stack software development, product design, cloud hosting, and MVP deployment. | Nov 11, 2025 | |
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $60.3M / Series B / Jul 19, 2024 | |
|
Cosmos Innovation
|
Cosmos Innovation specialize in full stack software development, product design, cloud hosting, and MVP deployment. | $16.8M / Series A / Oct 16, 2023 | |
Atom Computing
|
Atom Computing builds truly scalable quantum computers out of individual atoms.The company's quantum computers use quantum mechanical properties of atoms to process information and solve problems beyond the reach of traditional computers, including drug design, computational chemistry, and more.Atom Computing was founded in 2018 and basedin Berkeley, California. | $60M / Series B / Jan 20, 2022 | |
Anyword
|
Keywee offers publishers and marketers a new approach to content distribution and performance measurement. Its revolutionary platform employs advanced text-mining technology and a vast database of historical content performance to help publishers, retailers, and brands find the audiences most likely to meet specific business goals for theircontent. Keywee’s customers include The British Broadcasting Corporation (BBC), Conde Nast, National Geographic, The New York Times, and Slate. Backed by leading investors including Eric Schmidt’s Innovation Endeavors and Marker LLC, as well as The New York Times Company.Founded in 2013, the company is headquartered in New York with an office in Tel Aviv. | $21M / Series B / Nov 18, 2021 | |
|
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $25M / Series A / Nov 01, 2021 | |
Vicarious Surgical
|
Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. | $142M / Post-IPO Equity / Sep 20, 2021 | |
|
Atom Computing
|
Atom Computing builds truly scalable quantum computers out of individual atoms.The company's quantum computers use quantum mechanical properties of atoms to process information and solve problems beyond the reach of traditional computers, including drug design, computational chemistry, and more.Atom Computing was founded in 2018 and basedin Berkeley, California. | $15M / Series A / Jul 21, 2021 | |
Eikon Therapeutics
|
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $148M / Series A / May 05, 2021 | |
| See all 20 investments → | |||
Co-Investors
About Color
Color is a population health technology company that focuses on providing large-scale health care programs and clinical testing. It improves the key health infrastructure systems to make health accessible, convenient, and cost-effective, serving health systems, employers, research institutions, and individual consumers.Its Population GenomicsPlatform offers modular and end-to-end solutions that enable organizations to effectively build and scale population health programs. It provides technology, software, and clinical services to help population programs launch and scale quickly. By combining innovative technology, specialized laboratory infrastructure, and clinical health services, Color creates complete and effective programs that include: Program strategy, planning, and implementation; Participant outreach and engagement; participant education and consent about testing and results; sample (blood or saliva) collection and genetic sequencing; data management and clinical reporting; HIPAA compliance and data security; return of results; clinical services, like genetic counseling and clinical pharmacy; personalized care routine; and ongoing population health management. Color’s partners include NorthShore University Health System, the National Institutes of Health (NIH), Ochsner Health System, Verily, Visa, Levi Strauss, and Salesforce.Elad Gil, Nish Bhat, Taylor Sittler, and Othman Laraki launched Color in 2015 and is based in Burlingame, California.
Color Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Claire Vo
Chief Product Officer
|
|||
Elad Gil
Co-founder
|
|||
Alicia Zhou
VP of Research and Scientific Affairs
|
|||
Caroline Savello
VP of Commercial
|
|||
|
Dror Berman
Investor (Seed round and on)
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dror Berman invest in?
Dror Berman invests primarily in Software, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dror Berman last invest?
The most recent investment recorded for Dror Berman closed in Feb 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
